{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:17:59Z","timestamp":1790853479740,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Quality Foundation of the Dutch Association of Medical Specialists"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10549-019-05180-5","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T08:38:44Z","timestamp":1551429524000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands"],"prefix":"10.1007","volume":"175","author":[{"given":"Carmen","family":"van Dooijeweert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette A. G.","family":"Deckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge O.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsken","family":"van der Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-2745","authenticated-orcid":false,"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"5180_CR1","unstructured":"The Netherlands Comprehensive Cancer Organization (IKNL). Breast Cancer Guideline 2017 [updated 2012-07-02]. Available from: https:\/\/www.oncoline.nl\/borstkanker . Accessed 17 Jan 2019"},{"issue":"8","key":"5180_CR2","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A et al (2015) Tailoring therapies\u2014improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533\u20131546","journal-title":"Ann Oncol"},{"issue":"3","key":"5180_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-013-2827-0","volume":"143","author":"AE McCullough","year":"2014","unstructured":"McCullough AE, Dell\u2019orto P, Reinholz MM et al (2014) Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06\/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat 143(3):485\u2013492","journal-title":"Breast Cancer Res Treat"},{"key":"5180_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","volume":"75","author":"MJ Duffy","year":"2017","unstructured":"Duffy MJ, Harbeck N, Nap M et al (2017) Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on tumor markers (EGTM). Eur J Cancer 75:284\u2013298","journal-title":"Eur J Cancer"},{"issue":"9472","key":"5180_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687\u20131717","journal-title":"Lancet"},{"issue":"9793","key":"5180_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u2013784","journal-title":"Lancet"},{"issue":"3","key":"5180_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00428-011-1132-8","volume":"459","author":"H Choritz","year":"2011","unstructured":"Choritz H, Busche G, Kreipe H (2011) Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch 459(3):283\u2013289","journal-title":"Virchows Arch"},{"issue":"21","key":"5180_CR8","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","volume":"32","author":"HJ Burstein","year":"2014","unstructured":"Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255\u20132269","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"5180_CR9","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S et al (2015) on behalf of the ESMO guidelines committee; primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl_5):v8\u2013v30","journal-title":"Ann Oncol"},{"issue":"16","key":"5180_CR10","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"MEH Hammond","year":"2010","unstructured":"Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology\/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784\u20132795","journal-title":"J Clin Oncol"},{"issue":"17","key":"5180_CR11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJA Bowles","year":"2012","unstructured":"Bowles EJA, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293\u20131305","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"5180_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac Safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8):1231\u20131238","journal-title":"J Clin Oncol"},{"issue":"31","key":"5180_CR13","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EH Romond","year":"2012","unstructured":"Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792\u20133799","journal-title":"J Clin Oncol"},{"key":"5180_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/modpathol.2016.164","volume":"30","author":"J R\u00fcschoff","year":"2016","unstructured":"R\u00fcschoff J, Lebeau A, Kreipe H et al (2016) Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Mod Pathol 30:217","journal-title":"Mod Pathol"},{"issue":"21","key":"5180_CR15","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","volume":"28","author":"SD Russell","year":"2010","unstructured":"Russell SD, Blackwell KL, Lawrence J et al (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the north central cancer treatment group N9831 clinical trials. J Clin Oncol 28(21):3416\u20133421","journal-title":"J Clin Oncol"},{"issue":"31","key":"5180_CR16","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997\u20134013","journal-title":"J Clin Oncol"},{"issue":"5","key":"5180_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12094-011-0663-4","volume":"13","author":"M Cuadros","year":"2011","unstructured":"Cuadros M, Cano C, Lopez FJ et al (2011) HER2 status in breast cancer: experience of a Spanish National reference centre. Clin Transl Oncol 13(5):335\u2013340","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"5180_CR18","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1186\/bcr3384","volume":"15","author":"C Denkert","year":"2013","unstructured":"Denkert C, Huober J, Loibl S et al (2013) HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 15(1):R11","journal-title":"Breast Cancer Res"},{"key":"5180_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.breast.2016.09.015","volume":"30","author":"L Orlando","year":"2016","unstructured":"Orlando L, Viale G, Bria E et al (2016) Discordance in pathology report after central pathology review: implications for breast cancer adjuvant treatment. Breast 30:151\u2013155","journal-title":"Breast"},{"issue":"11","key":"5180_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/jnci\/94.11.852","volume":"94","author":"S Paik","year":"2002","unstructured":"Paik S, Bryant J, Tan-Chiu E et al (2002) Real-world performance of HER2 testing\u2014national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 94(11):852\u2013854","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"5180_CR21","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.2005.03.4744","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer treatment group N9831 intergroup adjuvant trial. J Clin Oncol 24(19):3032\u20133038","journal-title":"J Clin Oncol"},{"issue":"11","key":"5180_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnci\/94.11.855","volume":"94","author":"PC Roche","year":"2002","unstructured":"Roche PC, Suman VJ, Jenkins RB et al (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94(11):855\u2013857","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"5180_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/tbj.12858","volume":"24","author":"M Rosa","year":"2017","unstructured":"Rosa M, Khazai L (2017) Comparison of HER2 testing among laboratories: our experience with review cases retested at Moffitt Cancer Center in a two-year period. Breast J 24(2):139\u2013147","journal-title":"Breast J"},{"issue":"25","key":"5180_CR24","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","volume":"25","author":"G Viale","year":"2007","unstructured":"Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1\u201398. J Clin Oncol 25(25):3846\u20133852","journal-title":"J Clin Oncol"},{"issue":"2","key":"5180_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12253-014-9852-0","volume":"21","author":"S Bianchi","year":"2015","unstructured":"Bianchi S, Caini S, Paglierani M et al (2015) Accuracy and reproducibility of HER2 Status in breast cancer using immunohistochemistry: a quality control study in tuscany evaluating the impact of updated 2013 ASCO\/CAP recommendations. Pathol Oncol Res 21(2):477\u2013485","journal-title":"Pathol Oncol Res"},{"key":"5180_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/modpathol.3800774","volume":"20","author":"M Dowsett","year":"2007","unstructured":"Dowsett M, Hanna WM, Kockx M et al (2007) Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 20:584","journal-title":"Mod Pathol"},{"issue":"3","key":"5180_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1524-4741.2003.09325.x","volume":"9","author":"LJ Layfield","year":"2003","unstructured":"Layfield LJ, Goldstein N, Perkinson KR, Proia AD (2003) Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 9(3):257\u2013259","journal-title":"Breast J"},{"issue":"5","key":"5180_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1309\/PEF8-GL6F-YWMC-AG56","volume":"117","author":"RL Parker","year":"2002","unstructured":"Parker RL, Huntsman DG, Lesack DW et al (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117(5):723\u2013728","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"5180_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00428-002-0646-5","volume":"441","author":"P Regitnig","year":"2002","unstructured":"Regitnig P, Reiner A, Dinges HP et al (2002) Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 441(4):328\u2013334","journal-title":"Virchows Arch"},{"issue":"1","key":"5180_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1309\/H905-HYC1-6UQQ-981P","volume":"115","author":"A Rhodes","year":"2001","unstructured":"Rhodes A, Jasani B, Balaton AJ et al (2001) Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 115(1):44\u201358","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"5180_CR31","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.5858\/2006-130-1440-ICOITF","volume":"130","author":"PL Fitzgibbons","year":"2006","unstructured":"Fitzgibbons PL, Murphy DA, Dorfman DM et al (2006) Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 immunohistochemistry tissue microarray survey. Arch Pathol Lab Med 130(10):1440\u20131445","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"5180_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1309\/97WN-W6UX-XJWT-02H2","volume":"118","author":"A Rhodes","year":"2002","unstructured":"Rhodes A, Jasani B, Anderson E et al (2002) Evaluation of HER-2\/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 118(3):408\u2013417","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"5180_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/00000478-200207000-00005","volume":"26","author":"T Rudiger","year":"2002","unstructured":"Rudiger T, Hofler H, Kreipe HH et al (2002) Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 26(7):873\u2013882","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"5180_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1309\/URLK-6AVK-331U-0V5P","volume":"118","author":"R Wasielewski von","year":"2002","unstructured":"von Wasielewski R, Mengel M, Wiese B et al (2002) Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 118(5):675\u2013682","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"5180_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00428-008-0688-4","volume":"453","author":"R Wasielewski von","year":"2008","unstructured":"von Wasielewski R, Hasselmann S, Ruschoff J et al (2008) Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch 453(6):537\u2013543","journal-title":"Virchows Arch"},{"issue":"4","key":"5180_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/PAS.0b013e31820e6237","volume":"35","author":"LC Tong","year":"2011","unstructured":"Tong LC, Nelson N, Tsourigiannis J, Mulligan AM (2011) The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. Am J Surg Pathol 35(4):545\u2013552","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"5180_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","volume":"68","author":"EA Rakha","year":"2015","unstructured":"Rakha EA, Pinder SE, Bartlett JM et al (2015) Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 68(2):93\u201399","journal-title":"J Clin Pathol"},{"key":"5180_CR38","doi-asserted-by":"crossref","unstructured":"Lin CY, Carneal EE, Lichtensztajn DY et al Regional variability in percentage of breast cancers reported as positive for HER2 in California: implications of patient demographics on laboratory benchmarks. Am J Clin Pathol 148(3):199\u2013207","DOI":"10.1093\/ajcp\/aqx063"},{"issue":"1","key":"5180_CR39","first-page":"19","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch ATMG, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a Central Role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1):19\u201324","journal-title":"Cell Oncol"},{"key":"5180_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.humpath.2016.12.019","volume":"62","author":"Z Xian","year":"2017","unstructured":"Xian Z, Quinones AK, Tozbikian G, Zynger DL (2017) Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management? Hum Pathol 62:215\u2013221","journal-title":"Hum Pathol"},{"issue":"12","key":"5180_CR41","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.prp.2013.08.012","volume":"209","author":"YF Yang","year":"2013","unstructured":"Yang YF, Liao YY, Li LQ et al (2013) Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer. Pathol Res Pract 209(12):797\u2013802","journal-title":"Pathol Res Pract"},{"issue":"1","key":"5180_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12957-018-1332-7","volume":"16","author":"L Yang","year":"2018","unstructured":"Yang L, Zhong X, Pu T et al (2018) Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. World J Surg Oncol 16(1):51","journal-title":"World J Surg Oncol"},{"issue":"6797","key":"5180_CR43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"key":"5180_CR44","doi-asserted-by":"crossref","unstructured":"Spiegelhalter DJ. Funnel plots for comparing institutional performance. Stat Med 24(8):1185\u20131202","DOI":"10.1002\/sim.1970"},{"issue":"6","key":"5180_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/jcp.2004.022772","volume":"58","author":"HJ Huang","year":"2005","unstructured":"Huang HJ, Neven P, Drijkoningen M et al (2005) Association between tumour characteristics and HER-2\/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 58(6):611\u2013616","journal-title":"J Clin Pathol"},{"issue":"2","key":"5180_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1524-4741.2009.00689.x","volume":"15","author":"PS Sullivan","year":"2009","unstructured":"Sullivan PS, Apple SK (2009) Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J 15(2):146\u2013154","journal-title":"Breast J"},{"issue":"8","key":"5180_CR47","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/annonc\/mdl114","volume":"17","author":"M Tubiana-Hulin","year":"2006","unstructured":"Tubiana-Hulin M, Stevens D, Lasry S et al (2006) Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 17(8):1228\u20131233","journal-title":"Ann Oncol"},{"key":"5180_CR48","doi-asserted-by":"publisher","first-page":"469251","DOI":"10.1155\/2014\/469251","volume":"2014","author":"CA Parise","year":"2014","unstructured":"Parise CA, Caggiano V (2014) Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014:469251","journal-title":"J Cancer Epidemiol"},{"issue":"3","key":"5180_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jso.24516","volume":"115","author":"AC Bommel van","year":"2017","unstructured":"van Bommel AC, Spronk PE, Peeters MTV et al (2017) Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: the national NABON breast cancer audit. J Surg Oncol 115(3):243\u2013249","journal-title":"J Surg Oncol"},{"issue":"Suppl 5","key":"5180_CR50","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1245\/s10434-016-5532-5","volume":"23","author":"CH Deurzen van","year":"2016","unstructured":"van Deurzen CH (2016) Predictors of surgical margin following breast-conserving surgery: a large population-based cohort study. Ann Surg Oncol 23(Suppl 5):627\u2013633","journal-title":"Ann Surg Oncol"},{"issue":"2\u20133","key":"5180_CR51","first-page":"165","volume":"1198","author":"NE Hynes","year":"1994","unstructured":"Hynes NE, Stern DF (1994) The biology of erbB-2\/neu\/HER-2 and its role in cancer. Biochim Biophys Acta 1198(2\u20133):165\u2013184","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"5180_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","volume":"5","author":"MA Owens","year":"2004","unstructured":"Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5(1):63\u201369","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"5180_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1358\/dnp.2009.22.2.1334452","volume":"22","author":"JS Ross","year":"2009","unstructured":"Ross JS (2009) Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Dru News Perspect 22(2):93\u2013106","journal-title":"Dru News Perspect"},{"key":"5180_CR54","unstructured":"Foundation PALGA (2017) Annual report 2017. https:\/\/www.palga.nl\/assets\/uploads\/Jaarverslag\/Jaarverslag_2017_websiteversie.pdf . Accessed 17 Jan 2019"},{"issue":"6","key":"5180_CR55","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00428-016-1935-8","volume":"468","author":"CE Sluijter","year":"2016","unstructured":"Sluijter CE, van Lonkhuijzen LR, van Slooten HJ et al (2016) The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review. Virchows Arch 468(6):639\u2013649","journal-title":"Virchows Arch"},{"issue":"12","key":"5180_CR56","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdp234","volume":"20","author":"M Arnedos","year":"2009","unstructured":"Arnedos M, Nerurkar A, Osin P et al (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20(12):1948\u20131952","journal-title":"Ann Oncol"},{"key":"5180_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0153-0","author":"BZ Clark","year":"2018","unstructured":"Clark BZ, Onisko A, Assylbekova B et al (2018) Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity. Mod Pathol. https:\/\/doi.org\/10.1038\/s41379-018-0153-0","journal-title":"Mod Pathol"},{"issue":"3","key":"5180_CR58","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s10549-012-1990-z","volume":"134","author":"X Chen","year":"2012","unstructured":"Chen X, Yuan Y, Gu Z, Shen K (2012) Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat 134(3):957\u2013967","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"5180_CR59","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/annonc\/mds599","volume":"24","author":"TJ Dekker","year":"2013","unstructured":"Dekker TJ, Smit VT, Hooijer GK et al (2013) Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol 24(4):931\u2013937","journal-title":"Ann Oncol"},{"key":"5180_CR60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/1471-2407-10-534","volume":"10","author":"H Tsuda","year":"2010","unstructured":"Tsuda H, Kurosumi M, Umemura S et al (2010) HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer 10:534","journal-title":"BMC Cancer"},{"key":"5180_CR61","unstructured":"Dutch Institute for Clinical Auditing (DICA)\/ Netherlands Comprehensive Cancer Organisation\/ NABON Breast Cancer Audit (NBCA) (2018) Factsheet Indicators NABON Breast Cancer Audit (NBCA) 2018, version 2018.3"},{"key":"5180_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.breast.2017.12.015","volume":"38","author":"FH Groenendijk","year":"2018","unstructured":"Groenendijk FH, Jager A, Cardoso F, van Deurzen CHM (2018) A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer. Breast 38:125\u2013131","journal-title":"Breast"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05180-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T21:52:58Z","timestamp":1663019578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05180-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5180"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05180-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors CD (1), ID (2), IB (3) and EW (4) declare no conflict of interest. Author PD (5) received the SKMS research grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the scientific and privacy committee of PALGA (the nationwide registry of histo- and cytopathology in the Netherlands). As this study was performed retrospectively on anonymized data and did not involve subjecting patients to anything, consent from the ethics committee was not required according to the Dutch law. All data were retrieved and handled in compliance with the General Data Protection Regulation (GDPR).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All data from the PALGA database are pseudonymized by a trusted third party (ZorgTTP, Houten, the Netherlands). We only ever received fully anonymized data. Data of patients who object against the scientific use of their (anonymized) data are not included in the PALGA database. Therefore, waiver of informed consent is applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}